Neuvasq

SenyaTx

This company develops antibody-based therapeutics targeting the LRG1 protein to treat patients with chronic vascular diseases, including nephrology, oncology, and ophthalmology conditions.

VascVersa Ltd

This company develops vascular cell therapies to regenerate blood vessels for patients with ischaemic diseases, chronic wounds, and retinal vascular conditions.

Neurotech

This biotechnology company develops encapsulated cell therapy implants to treat chronic retinal diseases for patients with macular telangiectasia and other eye conditions.

Travin

This company develops blood-brain barrier shuttles for RNA therapeutics to enable the treatment of neurological diseases.

Therini Bio

The company develops fibrin-targeting monoclonal antibodies to treat patients with neurodegenerative and retinal diseases caused by vascular-mediated inflammation.

NovaGo Therapeutics

This clinical-stage biotechnology company develops human antibody therapeutics to promote nerve regeneration for patients with spinal cord injuries and strokes.

MindImmune Therapeutics

This company develops monoclonal antibody therapeutics to treat neurodegenerative diseases and neuroinflammation for patients with central nervous system disorders.

Coave Therapeutics

The company develops targeted gene therapies for patients with neurodegenerative and ocular diseases.